Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Financing Activities (2022 - 2025)

Atara Biotherapeutics' Cash from Financing Activities history spans 4 years, with the latest figure at -$3000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 99.09% year-over-year to -$3000.0; the TTM value through Dec 2025 reached $16.1 million, down 72.85%, while the annual FY2025 figure was $16.1 million, 72.85% down from the prior year.
  • Cash from Financing Activities reached -$3000.0 in Q4 2025 per ATRA's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $35.8 million in Q3 2024 to a low of -$328000.0 in Q4 2024.
  • Average Cash from Financing Activities over 4 years is $8.2 million, with a median of $759000.0 recorded in 2023.
  • The largest YoY upside for Cash from Financing Activities was 17308.17% in 2024 against a maximum downside of 168.79% in 2024.
  • A 4-year view of Cash from Financing Activities shows it stood at $32.3 million in 2022, then plummeted by 95.32% to $1.5 million in 2023, then tumbled by 121.69% to -$328000.0 in 2024, then surged by 99.09% to -$3000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Cash from Financing Activities are -$3000.0 (Q4 2025), $1.0 million (Q3 2025), and $15.3 million (Q2 2025).